Complementary pre-clinical offering on microbiota powered by Oncodesign At the forefront of precision medicine using microbiota signature

Scientific breakthrough in breast cancer
18/10/2019
[Congress] European Association of Nuclear Medicine Annual Meeting – 12-16 October – Barcelona – Spain
18/10/2019

Complementary pre-clinical offering on microbiota powered by Oncodesign At the forefront of precision medicine using microbiota signature

It is now known that the human microbiota, which consists of a wide variety of microorganisms, plays a much larger role in human health & disease than previously assumed.
Even if the causality is not always established, a microbial imbalance or dysbiosis has been reported in several diseases. It includes cancer, colitis, atopic dermatitis, diabetes, liver and lung fibrosis, multiple sclerosis, etc.

Oncodesign models for pathologies related to microbiota disorders and so can customize studies developped for programs from preclinical to early clinical phases.
Our thorough technologic and scientific knowledge in various therapeutic areas i.e. oncology, inflammatory and infectious diseases, allows us to support the development of microbiota-based therapies.

The influence of the microbiota on the effectiveness of cancer treatments, such as immunotherapies, has begun to be widely characterized in humans. It allowed the identification of beneficial or harmful bacteria and so to diagnostic or predictive drug efficacy biomarkers.

In this context, different approaches can be conceived to shape the gut microflora in order to reestablish anti-cancer immune responses in murine cancer models:

  • prebiotics that are products favoring the proliferation and function of beneficial bacterial species.
  • probiotics – it consists of single or mixtures of live bacterial species. This category can also include bacteriophages i.e viruses that kill bacteria with high target specificity,
  • fecal material transplant (autologous or allogeneic),

Established in-house platforms

Access to additional expertise within consortium and with our partners




  • A large choice of inflammatory and oncology models/assays for in vitro and in vivo studies
  • Production of standardized batches of bacteria
  • Analysis of microbiota (“omics” technologies) in collaboration with Biofortis
  • Access to samples from patients/healthy donors, in collaboration with Biofortis
Share this